alloxan has been researched along with sirolimus in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, LL; Guo, CR; Ji, D; Li, F; Ruan, SX; Yang, ZL; Yuan, YL; Zhang, CF | 1 |
| Cain, C; Das, A; Filippone, SM; Kraskauskas, D; Kukreja, RC; Ockaili, R; Roh, SK; Samidurai, A | 1 |
2 other study(ies) available for alloxan and sirolimus
| Article | Year |
|---|---|
Timosaponin B-II ameliorates diabetic nephropathy via TXNIP, mTOR, and NF-κB signaling pathways in alloxan-induced mice.
Topics: Alloxan; Anemarrhena; Animals; Blood Glucose; Carrier Proteins; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Kidney; Male; Mice; Mice, Inbred ICR; NF-kappa B; Saponins; Signal Transduction; Sirolimus; Steroids; Thioredoxins | 2015 |
Preclinical model of type 1 diabetes and myocardial ischemia/reperfusion injury in conscious rabbits-demonstration of cardioprotection with rapamycin.
Topics: Alloxan; Animals; Apoptosis; Balloon Occlusion; Cardiotonic Agents; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Disease Models, Animal; Electrocardiography; Male; Myocardial Reperfusion Injury; Rabbits; Sirolimus; Troponin I | 2021 |